Real-world outcomes with lurbinectedin in second-line setting and beyond for extensive stage small cell lung cancer

Clinical trials have demonstrated efficacy and safety of lurbinectedin for relapsed small cell lung cancer (SCLC), but real-world data are limited. A retrospective study at the Mayo Clinic Health System evaluated second or later line lurbinectedin for extensive stage SCLC in the real world. Lurbinectedin was generally well tolerated, with a median overall survival of 5.1 months in the second-line cohort and 5.6 months in the third-line or later cohort. Adverse events were manageable. There were no treatment-related deaths. The authors conclude that lurbinectedin in the real world demonstrated modest efficacy and a comparable safety profile to that in clinical trials, regardless of line of therapy.